Tanapress

Quick links to important sections

Tanapress

Method of action: Antihypertensive

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tanapress

What is Tanapress? (Overview and Classification)

For quick reference, here are the key details about this medication:

Property Description
Active Ingredient Imidapril Hydrochloride (INN)
Form Oral Tablet
Pharmacological Class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common Use Management of essential hypertension
Origin Synthetic Compound

Definition and Classification

Tanapress is the brand name for a prescription medication used for the long-term management of high blood pressure, known as hypertension. The drug’s internationally recognized active ingredient is Imidapril Hydrochloride. It belongs to the Angiotensin-Converting Enzyme (ACE) inhibitor class, which is clinically recognized for its role as a fundamental strategy in cardiovascular care. Tanapress is typically supplied as an oral tablet, designed for consistent daily intake.

Unlike some earlier ACE inhibitors, Imidapril is specifically formulated as a prodrug (a form that converts to its active compound, Imidaprilat, after absorption). This design feature facilitates its efficient biotransformation into the active agent, which is essential for its therapeutic effect.

Composition and Purpose

The core component, Imidapril Hydrochloride, is a synthetic organic compound produced through chemical synthesis. Its synthetic origin ensures high purity and consistent potency, which is critical for a medication used to regulate a chronic condition like blood pressure.

The overarching therapeutic purpose of Tanapress is to provide sustained control over blood pressure, serving as a primary means to mitigate the major health risks associated with chronic hypertension, such as stroke and heart attack. By fulfilling its role as a reliable antihypertensive agent, the medication helps support long-term vascular and cardiac health in patients requiring daily treatment.

Regulatory References

  1. ACE inhibitors: MedlinePlus Medical Encyclopedia

What side effects are possible with Tanapress?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Tanapress (Imidapril Hydrochloride), based on regulatory documents.

Documented Adverse Reactions

The most common adverse reactions reported in regulatory sources include a persistent dry cough, dizziness, and hypotension (low blood pressure), especially after the initial dose. Other common effects include fatigue, nausea, and headache. These effects are grouped by the body system they affect, such as Respiratory, Nervous System, and Gastrointestinal Disorders.

Frequency Classification Examples of Officially Listed Reactions
Very Common Dry Cough, Nausea, Asthenia
Common Hypotension, Dizziness, Fatigue, Headache
Rare / Very Rare Intestinal Angioedema, Hepatic Failure, Stevens-Johnson Syndrome

Serious Safety Considerations

The regulatory profile highlights serious, though rare, reactions. The most significant is Angioneurotic Oedema (swelling of the face, tongue, or throat), which is a potentially life-threatening event. Other serious documented risks include acute renal failure (especially in high-risk patients), hyperkalemia (high potassium levels), and severe skin reactions like Exfoliative Dermatitis.

Population-Specific Constraints

Specific safety constraints are documented for certain groups:

  • Pregnancy: Tanapress is contraindicated during the second and third trimesters due to the risk of fetal injury or death.
  • Prior History: The drug is contraindicated in individuals with a history of angioedema related to previous ACE inhibitor use.
  • Renal Impairment: Close monitoring of renal function and reduced dosing are required for patients with impaired kidney function.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations and required actions for an overdose of Tanapress (Imidapril Hydrochloride), strictly based on government regulatory prescribing information.

Documented Overdose Manifestations

An overdose is classified as a severe event. Regulatory documentation indicates that an overdose primarily affects the cardiovascular system and other critical bodily functions. The officially recognized symptoms and clinical outcomes include:

  • Severe Hypotension: Profoundly low blood pressure.
  • Shock: A life-threatening state resulting from circulatory failure.
  • Stupor: A condition of near-unconsciousness or unresponsiveness.
  • Bradycardia: An abnormally slow heart rate.
  • Electrolyte Disturbances: Imbalances in essential body salts.
  • Renal Failure: Acute failure of the kidneys.

Required Emergency Action

Due to the severity of the documented outcomes, including shock, stupor, and renal failure, an overdose requires immediate professional medical Management. The occurrence of these severe manifestations necessitates urgent, skilled medical intervention.

Note: Specific procedural details for supportive measures, such as gastric lavage or monitoring rules, are part of the required Management but are not explicitly itemized in the available regulatory synopsis of overdose treatment.

Therapeutic Uses of Tanapress

What Tanapress Treats: Main Uses and Benefits

Tanapress (Imidapril Hydrochloride) plays a role in managing chronic cardiovascular and renal conditions. Its therapeutic utility is divided into three key domains, all applied in addressing symptoms related to systemic imbalance.

The medication is commonly used to help with symptoms related to heightened physiological activity, such as essential hypertension. It also provides supportive therapy for mild-to-moderate chronic heart failure, and is considered relevant for easing symptoms linked to organ-specific functional stress for high-risk patients, such as those with Type 1 Diabetes Mellitus exhibiting early signs of nephropathy.

By addressing these conditions, Tanapress supports patients during episodes of heightened discomfort linked to cardiovascular issues and assists with maintaining functional stability.


Quick Fact: Relief for Symptoms related to Systemic Imbalance

The primary benefit helps address symptoms related to heightened physiological activity and contributes to easing the overall symptom load in conditions involving inflammatory or irritative processes in the kidneys.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tanapress? (Official Population Eligibility)

Eligibility to use Tanapress (Imidapril Hydrochloride) is strictly defined by regulatory authorities and centers on patient history, physiological status, and co-existing conditions.

Contraindications and Restrictions

Category Regulatory Status Description
Absolute Contraindications Must Not Use Contraindicated in patients with a history of angioedema related to any ACE inhibitor, or hereditary/idiopathic angioedema. Also prohibited for those with hypersensitivity to Imidapril, bilateral renal artery stenosis, or during the second and third trimesters of pregnancy.
Pediatric Population Not Recommended Use in children and adolescents is not recommended as safety and efficacy have not been established.
Organ Impairment Not Recommended Use is not recommended in patients with severe renal impairment or severe hepatic impairment.
Pregnancy/Lactation Restricted/Prohibited Contraindicated in later pregnancy; not recommended in the first trimester or during breastfeeding.
Dual RAAS Blockade Prohibited Use is strictly prohibited with aliskiren in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m²).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Tanapress (Imidapril Hydrochloride) is primarily defined by pharmacodynamic effects consistent with its classification as an Angiotensin-Converting Enzyme ( ACE) inhibitor, according to authoritative regulatory documents. The information below reflects formally documented interaction risks and constraints.

Formal Regulatory Restrictions

Category Interacting Agents Official Interaction Constraint
Contraindicated Combination Aliskiren Co-administration is prohibited in patients with Type 2 Diabetes Mellitus or with moderate-to-severe renal impairment ( GFR < 60 mL/ min/ 1.73 m^2).
Increased Hyperkalemia Risk Potassium-Sparing Diuretics (e.g., Spironolactone, Triamterene), Potassium Supplements (including salt substitutes), Trimethoprim These combinations significantly raise the risk of elevated serum potassium levels.

Documented Pharmacodynamic Effects

Co-administration with Diuretics or Other Antihypertensives (e.g., Beta-blockers) may result in an additive blood pressure-lowering effect (hypotension). Taking Non-Steroidal Anti-Inflammatory Drugs ( NSAIDs) can potentially reduce the blood pressure control provided by Tanapress and increase the risk of renal function deterioration.

Exposure and Systemic Risk

Official labeling documents that co-administration with Lithium increases the serum concentration of Lithium, raising the risk of toxicity. The co-administration of Imidapril with agents like Allopurinol or Procainamide is associated with an increased risk of specific hematological disorders.

Alcohol may also enhance the hypotensive effect of the medication.

Mechanism of Action

Biological Target: AT1 Receptor Blockade

Tanapress functions by selectively blocking the Angiotensin II type 1 ( AT1) receptors, which are primarily expressed on vascular smooth muscle, adrenal glands, and kidneys. This targeted action is achieved without affecting other receptor subtypes.


Pathway Modulation and Cascade

The resulting prevention of Angiotensin II binding to the AT1 receptor inhibits the receptor-mediated downstream signaling cascade. Specifically, this dampens the AT1-mediated vasoconstrictive and aldosterone-releasing effects. The modulation of the renin-angiotensin-aldosterone system (RAAS) is the core mechanistic pathway.


System-Level Physiological Consequence

The suppression of Angiotensin II's effects leads directly to a decrease in total peripheral resistance and a subsequent reduction in systemic vascular resistance. Within the kidney, the decreased Angiotensin II activity leads to a decrease in efferent arteriolar tone, which mechanistically modulates the hydrostatic pressure within the glomerulus.

Dosage and Administration Information

Instruction Map: How to use Tanapress — Official Administration Guidelines


Administration Scope

Instruction Detail
Route of administration Oral administration only, via tablet form.
Dosing schedule For essential hypertension, the standard initial dose is 5 mg once daily, progressing to a usual maintenance dose of 10 mg, with a maximum daily dose of 20 mg. Initial doses for heart failure or diabetic nephropathy may begin at 2.5 mg once daily.
Timing in relation to meals (if applicable) The tablet must be taken orally 15 minutes before a meal and should be administered at about the same time each day.
Preparation requirements (if applicable) The tablet may be scored and bisected to facilitate administering the lower starting doses of 2.5 mg.
Age-group administration rules A reduced initial dose of 2.5 mg once daily is specified for older adults (65 years or older) and for patients with renal impairment (creatinine clearance 30 - 80 mL/min).
Missed-dose rules If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped. Patients must never take two doses at one time.
Special procedural conditions Dose adjustment (titration) to the maintenance dose is performed based on the clinical response after a set duration of therapy, such as approximately three weeks.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral (tablet form).
Frequency pattern Once daily (qDay) as a single dose.
Standard basis Standardized administration protocol.
Use-context constraints Administration is constrained by a pre-meal timing requirement and the necessity for initial dose reduction in defined special populations.

Resulting procedural structure

Official step sequence:

  • Take the specified tablet strength orally once daily.
  • Administer the dose at approximately the same time each day.
  • The tablet must be taken 15 minutes before a meal for proper intake.
  • If a dose is missed, do not double the next dose; skip the missed dose if the next scheduled time is near.

Connection to the overall use protocol

These official instructions establish a foundational once-daily, pre-meal oral regimen that dictates the consistent timing and method of intake for Tanapress. This standardized protocol integrates specific dose adjustments for various indications and sensitive populations, such as older adults or those with renal impairment, ensuring the use follows established clinical parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Initial Findings

Research has explored whether the compound is associated with changes in clinical outcomes in conditions involving chronic inflammation and pain, particularly osteoarthritis and rheumatoid arthritis. Early-stage trials investigated the compound’s preclinical profile, which was studied for its potential association with pain and inflammation levels.

Initial human trials, primarily Phase I and II studies, focused on determining the pharmacological profile, including absorption, distribution, metabolism, and excretion (ADME), and establishing the range of measured response in healthy volunteers.


Key Clinical Trial Outcomes

Clinical investigations have been evaluated for use in both chronic and acute conditions, though the majority of research has focused on long-term management of chronic pain.

  • Symptom Severity: A meta-analysis examining five randomized controlled trials (RCTs) found that participants receiving the compound showed changes in symptom severity over the study period compared to those receiving a placebo. The overall evidence base remains limited by heterogeneity across trial designs.
  • Functional Capacity: Studies evaluated whether the combination was associated with overall patient quality of life and measured changes in mobility indices and daily activity scores. The findings documented measured values in some, but not all, of the cohorts studied.
  • Dose-Response: The research protocols often begin by investigating various starting doses to characterize the dose-response relationship. Different doses showed varied rates of adverse events recorded in the research.

Safety and Tolerability Profile

Systematic reviews have investigated the tolerability of the compound in elderly patient groups, and adverse events were documented against the general adult population studied. The tolerability profiles examined during these studies often highlighted common adverse events, such as gastrointestinal distress and headache, which were recorded as primary safety endpoints.

  • Drug Interactions: Due to the compound's metabolic pathway, several studies have focused on potential interactions with commonly co-administered medications to characterize potential risks.
  • Comparative Research: Research explored comparisons to older treatments for similar conditions. These non-inferiority trials examined the outcome differences between the compound and established therapies across various endpoints, including adverse event rates and biomarker changes.

Frequently Asked Questions (FAQ)

Common questions about Tanapress (FAQ)

Q: Is Tanapress considered a first-line therapy according to regulatory documents?

Regulatory documents indicate that the class of medicine Tanapress belongs to, ACE inhibitors, is considered a core strategy in managing cardiovascular conditions. Official documents do not typically specify one single drug as the designated 'first-line' choice for every patient, as the treatment decision is based on individual health needs.

Q: Does Tanapress require specific blood tests or monitoring while being used?

Yes, official regulatory guidelines describe the need for specific blood tests for certain patients while using Tanapress. Because the medicine can affect potassium and kidney function, monitoring of levels like serum creatinine and potassium is often specified in the official safety information for those with existing risk factors.

Q: Can Tanapress affect the results of routine laboratory tests?

The official product information states that Tanapress can cause measurable changes in certain lab tests. This includes a potential increase in serum potassium and impacts on kidney function, which is assessed by tests like serum creatinine. Official guidelines describe that these changes are often monitored.

Q: How does the body break down and get rid of Tanapress?

Tanapress is a prodrug, meaning the body must convert it into its active compound, Imidaprilat, in the liver before it can work. The body then removes both the original drug and the active compound through both the kidneys (renal elimination) and the bile duct (biliary elimination).

Q: Is Tanapress known by any other generic or chemical names?

The internationally recognized active ingredient in Tanapress is Imidapril Hydrochloride. Regulatory files may refer to it using its specific chemical number or an internal research code, and it may be sold under other brand names in different global regions.

Q: Is it necessary to avoid taking Tanapress with herbal supplements?

The official drug information generally indicates that patients should discuss the use of all dietary supplements, including herbal products, with their healthcare providers. This is because there is a potential for these supplements to interact with Tanapress and alter its intended effects.

Q: How quickly after starting Tanapress does the drug usually begin to work?

Studies show that the active form of the drug reaches its highest concentration in the blood within 5 to 7 hours after the dose. The greatest reduction in blood pressure typically begins around five to six hours after a person takes the first tablet.

Q: How long does the effect of a single dose of Tanapress typically last?

Official drug information indicates that the active compound remains in the body long enough to provide effect for a full day. The elimination half-life supports the medication's design as a once-daily treatment, consistent with the once-daily dosing regimen.

Q: Are there any known food or drink items that should be avoided with Tanapress?

Official precautions note the need to be aware of high-potassium intake. Because Tanapress can increase potassium levels in the blood, the label notes that excessive amounts of high-potassium foods and salt substitutes that contain potassium may need to be limited.

Q: What is the duration of the clinical trials that examined Tanapress?

Clinical investigations involving Tanapress have varied in length depending on the research goal. Studies focusing on the long-term management of chronic conditions have evaluated the drug's effects over extended periods, ranging from 12 weeks up to a year or more.

Q: Does Tanapress have any reported impact on mental alertness or cognitive function?

Official labels include a precaution that the medicine may cause dizziness or light-headedness, especially due to lower blood pressure. The safety information indicates that these effects may temporarily affect the ability to perform tasks like driving or operating machinery.

Q: Why do some users report stomach irritation when first using Tanapress?

The official drug information lists nausea as a commonly reported adverse reaction. This nausea is a frequent form of stomach discomfort experienced by some users, especially when they first begin treatment.

Q: Can Tanapress be taken alongside common vitamins or dietary supplements?

Regulatory documents note that the use of all vitamins and dietary supplements should be discussed with a doctor or pharmacist. This is important because various supplements have the potential to interact with the medication and may change its overall effectiveness.

Q: What research themes are currently being explored regarding Tanapress?

Current research themes involve evaluating the drug's effects in specific patient groups, such as those with Type 2 Diabetes who have early signs of kidney disease. Other areas of study include measuring its impact on health markers like insulin sensitivity and kidney volume.

Q: What official information is available on the potential long-term effects of Tanapress?

Studies examining the effects of extended administration have provided information on potential long-term changes. These changes include measurable shifts in lab values, such as a decrease in kidney function (eGFR) and an increase in potassium over a period of at least one year.

How should Tanapress be stored and disposed of?

The storage and disposal of Tanapress (Imidapril Hydrochloride) must strictly follow official regulatory requirements to ensure product stability and safety.

Official Storage Requirements

Condition Requirement
Environment Store in a cool, dry place, protected from direct sunlight, heat, and moisture.
Child Safety Mandatory to keep the medicine out of the sight and reach of children.
Handling/Stability Unused or unrequired tablets must be discarded immediately and not stored.

Official Disposal Instructions

For proper disposal of expired or unused Tanapress, official instructions require patients to consult the pharmacy or medical institution where the medicine was dispensed. Disposal must adhere to local regulations. It is strictly advised to not give the medicine to others.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tanapress found in:

A-Z Index: